Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on trackPALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) $VTGN #mentalhealth Vistagen (Nasdaq: VTGN), a late clinical-stag.
VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond (NASDAQ:VTGN) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.